#1 Clinical Trials Search in Europe

Ipratropium Bromide

Ipratropium Bromide, commonly known by its brand name Atrovent, is a medication used in various respiratory conditions. This article examines its use in clinical trials for conditions like asthma, chronic obstructive pulmonary disease (COPD), and other respiratory issues. We’ll explore how this anticholinergic bronchodilator is being studied to improve breathing and quality of life for patients with respiratory challenges.

Table of Contents

What is Ipratropium Bromide?

Ipratropium Bromide is a medication commonly used to treat various respiratory conditions. It belongs to a class of drugs called anticholinergics or antimuscarinic agents. This medication is also known by its brand name Atrovent[1][2]. Ipratropium Bromide works by relaxing the muscles in your airways, making it easier to breathe[3].

Conditions Treated with Ipratropium Bromide

Ipratropium Bromide is used to treat several respiratory conditions, including:

  • Chronic Obstructive Pulmonary Disease (COPD): This is a group of lung diseases that cause airflow blockage and breathing-related problems[3].
  • Asthma: A condition in which your airways narrow and swell and may produce extra mucus[2].
  • Exercise-Induced Bronchospasm: This is a narrowing of the airways in the lungs that occurs in response to exercise[2].
  • Sialorrhea: Excessive drooling, which can be a problem in children with certain neurological conditions[1].

How Ipratropium Bromide Works

Ipratropium Bromide works by blocking the action of a chemical in your body called acetylcholine. This chemical normally causes the muscles in your airways to tighten. By blocking acetylcholine, Ipratropium Bromide helps to relax these muscles, which widens your airways and makes breathing easier[3].

In the case of sialorrhea (excessive drooling), Ipratropium Bromide works by reducing the production of saliva when applied sublingually (under the tongue)[1].

How Ipratropium Bromide is Administered

Ipratropium Bromide is typically administered in the following ways:

  • Inhaler: A metered-dose inhaler (MDI) that delivers the medication directly to your lungs[2].
  • Nebulizer: A device that turns the medication into a fine mist that you can inhale[3].
  • Spray: For conditions like sialorrhea, it may be administered as a spray under the tongue[1].

The dosage and frequency of use depend on the condition being treated and the severity of symptoms. Always follow your healthcare provider’s instructions carefully.

Effectiveness of Ipratropium Bromide

Research has shown that Ipratropium Bromide can be effective in managing various respiratory conditions:

  • In COPD patients, it has been shown to improve lung function, reduce dyspnea (shortness of breath), increase exercise tolerance, and enhance quality of life[3].
  • For asthma patients, it can help prevent exercise-induced bronchospasm when used before physical activity[2].
  • In children with sialorrhea, it may help reduce excessive drooling when applied as a sublingual spray[1].

Ongoing Research and Future Potential

Researchers continue to study Ipratropium Bromide to understand its full potential and explore new applications:

  • A study is investigating its effectiveness in treating Exercise-Induced Laryngeal Obstruction (EILO), a condition that causes breathing difficulties during exercise[4].
  • Another study is exploring its use in managing respiratory emergencies in children, potentially reducing the need for hospitalization[5].
  • Researchers are also investigating its role in managing asthma patients with fixed airway obstruction, which could lead to earlier use of anticholinergic medications in asthma treatment[6].

These ongoing studies may expand our understanding of Ipratropium Bromide’s benefits and potentially lead to new treatment strategies for various respiratory conditions.

Aspect Details
Main Uses in Trials Asthma, COPD, Exercise-Induced Laryngeal Obstruction, Sialorrhea
Administration Methods Inhaled spray, Nebulizer, Metered-dose inhalers
Key Outcomes Measured Lung function (FEV1), Breathing difficulties, Hospital admissions
Patient Groups Adults with COPD, Children with asthma, Athletes, Patients with EILO
Comparative Studies Compared with placebo and other bronchodilators like salbutamol
Unique Applications Peri-operative use in COPD patients, Treatment of drooling in children

FAQ

  • What is Ipratropium Bromide used for in clinical trials? Ipratropium Bromide is being studied in clinical trials for various respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), exercise-induced laryngeal obstruction (EILO), and sialorrhea (excessive drooling) in children.
  • How does Ipratropium Bromide work? Ipratropium Bromide is an anticholinergic bronchodilator. It works by relaxing the muscles in the airways, which helps to open up the breathing passages and make breathing easier.
  • What are some potential benefits of Ipratropium Bromide observed in clinical trials? Clinical trials have shown potential benefits such as improved lung function, reduced breathing difficulties, prevention of exercise-induced bronchoconstriction in athletes, and possible reduction in hospital admissions for children with asthma when used in emergency situations.
  • Are there any side effects of Ipratropium Bromide noted in clinical trials? While specific side effects weren't detailed in the provided trial information, anticholinergic medications like Ipratropium Bromide can generally cause dry mouth, cough, and headache. Always consult with a healthcare provider for a full list of potential side effects.
  • How is Ipratropium Bromide typically administered in clinical trials? In the clinical trials described, Ipratropium Bromide was administered in various ways, including as an inhaled spray, through a nebulizer, or as metered-dose inhalers. The dosage and frequency varied depending on the specific study and condition being treated.

Ongoing Clinical Trials on Ipratropium Bromide

  • Study on Oxygen Therapy and Salbutamol for Patients with COPD Exacerbation

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on the Effects and Safety of Dupilumab for Children Aged 2 to Under 6 with Uncontrolled Asthma or Severe Asthmatic Wheeze

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +3

Glossary

  • Anticholinergic: A type of medication that blocks the action of acetylcholine, a neurotransmitter that affects muscle contractions in the body, including in the airways.
  • Bronchodilator: A substance that dilates the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs.
  • COPD (Chronic Obstructive Pulmonary Disease): A group of lung diseases that block airflow and make it difficult to breathe.
  • Exercise-Induced Laryngeal Obstruction (EILO): A condition where the larynx (voice box) closes inappropriately during high-intensity exercise, causing breathing difficulties.
  • Sialorrhea: Excessive production of saliva, also known as drooling.
  • Spirometry: A common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
  • FEV1 (Forced Expiratory Volume in 1 second): The amount of air a person can force from their lungs in one second. It is an important measure of lung function.
  • Bronchoconstriction: The tightening of the muscles around the airways, which can make breathing difficult.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind study: A study in which neither the participants nor the researchers know who is receiving the experimental treatment and who is receiving a placebo or standard treatment.

References

  1. https://clinicaltrials.gov/study/NCT03747536
  2. https://clinicaltrials.gov/study/NCT01691079
  3. https://clinicaltrials.gov/study/NCT00202176
  4. https://clinicaltrials.gov/study/NCT02755714
  5. https://clinicaltrials.gov/study/NCT06074185
  6. https://clinicaltrials.gov/study/NCT05550402